24/7 Market News Snapshot 18 August, 2025 – Catheter Precision, Inc. (NYSE:VTAK)

August 18, 2025

DENVER, Colo., 18 August, 2025 (www.247marketnews.com) – (NYSE:VTAK) are discussed in this article.
Catheter Precision, Inc. is experiencing a significant upswing in its market performance as its stock price surges to $4.609 in pre-market trading, reflecting a remarkable increase of 76.59% from the previous close of $2.610. This surge, driven by a robust trading volume of 8.18 million shares, highlights the growing enthusiasm among investors and positions the company favorably in the competitive landscape of medical devices. Technical indicators suggest sustained momentum, inviting traders and market participants to closely monitor this dynamic stock.

In parallel with its impressive stock performance, Catheter Precision has achieved a pivotal milestone with the recent approval of its innovative LockeT device for entry into the United Kingdom market. The LockeT, a sophisticated suture retention device designed to improve wound closure after venous punctures, was granted CE Mark approval in May 2025, confirming its compliance with rigorous safety and efficacy standards.

The collaboration with HC21, a prominent UK value-added distributor boasting an annual revenue of €180 million, positions Catheter Precision strategically for a successful market introduction. This partnership builds on a foundation of mutual success, enabling both entities to leverage established channels to expedite the distribution of the LockeT.

Fatih Ayoglu, the Sales Manager for EMEA & APAC at Catheter Precision, remarked on this achievement, emphasizing the company’s commitment to enhancing patient care with innovative solutions that improve recovery and efficiency in cardiac procedures. The LockeT aligns with the NHS’s objectives to address waiting lists and provide superior patient care, allowing healthcare professionals to facilitate treatments more effectively.

As Catheter Precision continues to advance in cardiac technologies, its commitment to patient-centric solutions remains unwavering, emphasizing collaboration with the healthcare community to foster improved outcomes for patients across the United Kingdom.

Related news for (VTAK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.